JP2025513851A5 - - Google Patents
Info
- Publication number
- JP2025513851A5 JP2025513851A5 JP2024560405A JP2024560405A JP2025513851A5 JP 2025513851 A5 JP2025513851 A5 JP 2025513851A5 JP 2024560405 A JP2024560405 A JP 2024560405A JP 2024560405 A JP2024560405 A JP 2024560405A JP 2025513851 A5 JP2025513851 A5 JP 2025513851A5
- Authority
- JP
- Japan
- Prior art keywords
- capsid
- pharmaceutical composition
- aav
- viral vector
- itr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330245P | 2022-04-12 | 2022-04-12 | |
| US63/330,245 | 2022-04-12 | ||
| PCT/US2023/065689 WO2023201274A1 (en) | 2022-04-12 | 2023-04-12 | Use of an irak4 modulator for gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513851A JP2025513851A (ja) | 2025-04-30 |
| JP2025513851A5 true JP2025513851A5 (OSRAM) | 2026-04-20 |
Family
ID=86329943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560405A Pending JP2025513851A (ja) | 2022-04-12 | 2023-04-12 | 遺伝子治療のためのｉｒａｋ４モジュレーターの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405014A1 (OSRAM) |
| EP (1) | EP4508226A1 (OSRAM) |
| JP (1) | JP2025513851A (OSRAM) |
| KR (1) | KR20250004738A (OSRAM) |
| CN (1) | CN119343458A (OSRAM) |
| AU (1) | AU2023253700A1 (OSRAM) |
| CA (1) | CA3248216A1 (OSRAM) |
| IL (1) | IL316222A (OSRAM) |
| MX (1) | MX2024012617A (OSRAM) |
| TW (1) | TW202402329A (OSRAM) |
| WO (1) | WO2023201274A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025158385A1 (en) * | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| US7261544B2 (en) | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| KR101812813B1 (ko) | 2009-06-16 | 2017-12-27 | 젠자임 코포레이션 | 재조합 ａａｖ 벡터에 대한 개선된 정제 방법 |
| US20110070241A1 (en) * | 2009-06-30 | 2011-03-24 | Duke University | Methods for modulating immune responses to aav gene therapy vectors |
| EP3567106A1 (en) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2020264490A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021231575A1 (en) * | 2020-05-12 | 2021-11-18 | Myogene Bio Llc | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy |
| WO2021247897A1 (en) | 2020-06-03 | 2021-12-09 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
-
2023
- 2023-04-12 JP JP2024560405A patent/JP2025513851A/ja active Pending
- 2023-04-12 KR KR1020247037272A patent/KR20250004738A/ko active Pending
- 2023-04-12 WO PCT/US2023/065689 patent/WO2023201274A1/en not_active Ceased
- 2023-04-12 TW TW112113696A patent/TW202402329A/zh unknown
- 2023-04-12 EP EP23722240.1A patent/EP4508226A1/en active Pending
- 2023-04-12 CA CA3248216A patent/CA3248216A1/en active Pending
- 2023-04-12 AU AU2023253700A patent/AU2023253700A1/en active Pending
- 2023-04-12 US US18/299,640 patent/US20230405014A1/en active Pending
- 2023-04-12 CN CN202380044027.8A patent/CN119343458A/zh active Pending
- 2023-04-12 IL IL316222A patent/IL316222A/en unknown
-
2024
- 2024-10-10 MX MX2024012617A patent/MX2024012617A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP6619454B2 (ja) | キャプシド | |
| EP3221456B1 (en) | Genome-modified recombinant adeno-associated virus vectors | |
| JP2020530307A5 (OSRAM) | ||
| JP2021106619A5 (OSRAM) | ||
| EP0862643B1 (en) | Accessory functions for use in recombinant aav virion production | |
| JP2022508182A5 (OSRAM) | ||
| US6365403B1 (en) | High-efficiency AAV helper functions | |
| JP2020522269A5 (OSRAM) | ||
| JP2022530126A (ja) | 新規アデノ随伴ウイルス（ａａｖ）バリアント及び遺伝子治療のためのその使用 | |
| JP2017509632A5 (OSRAM) | ||
| CN106884014B (zh) | 腺相关病毒反向末端重复序列突变体及其应用 | |
| CN110606874A (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| JP2025178242A (ja) | Ａａｖ５の単離修飾ｖｐ１カプシドタンパク質 | |
| JP2025513850A5 (OSRAM) | ||
| CN111876432B (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
| JP2022551744A5 (OSRAM) | ||
| JP2017529395A5 (OSRAM) | ||
| JP2018515102A (ja) | スペーサーを含む核酸分子およびその使用の方法 | |
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| JP2023537358A5 (OSRAM) | ||
| JP2023541443A5 (OSRAM) | ||
| CN119343458A (zh) | Irak4调节剂用于基因疗法的用途 | |
| CN118064436B (zh) | 一种增强基因表达的嵌合启动子 | |
| Purohit et al. | Molecular characterization of novel Adeno-associated virus variants infecting human tissues |